» Articles » PMID: 18468308

Sleepiness and Sleep Disordered Breathing in Prader-Willi Syndrome: Relationship to Genotype, Growth Hormone Therapy, and Body Composition

Overview
Specialties Neurology
Psychiatry
Date 2008 May 13
PMID 18468308
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Study Objectives: Patients with Prader-Willi syndrome (PWS) suffer from excessive sleepiness and sleep disordered breathing (SDB). We reviewed the polysomnograms (PSGs) and multiple sleep latency tests (MSLTs) in a cohort of PWS patients to determine the relationship of BMI(Z) scores, daytime sleepiness, growth hormone (GH) treatments, and SDB.

Methods: Attended overnight PSGs were performed for PWS patients referred for concern for SDB between January 2000 and January 2005. Age at time of study, genotype, use and dose of GH, sleepiness scale, normalized body-mass index (BMI(Z)), total sleep time, latency to stage I and REM sleep, sleep stage percentages, apnea-hypopnea index (AHI), central apnea (CA) frequency, oxygen saturation nadir, maximum carbon dioxide tension, periodic limb movement index, presence of snoring, normality of EEG, and, in several patients, mean sleep latency testing were determined.

Results: All patients exhibited some form of SDB. There was a positive correlation between the BMI(Z) and AHI. The BMI(Z) was significantly different between GH-treated and -untreated groups, but there was not a significant difference between AHI, CA, oxygen nadir, or maximum carbon dioxide tension of the GH-treated and -untreated groups. There was no significant correlation between the MSLT and the sleepiness scale or AHI. There was also no significant difference between the AHIs of patients with different genetic defects.

Conclusions: There should be a low threshold for obtaining PSG to evaluate SDB, but the type and severity of SDB were not predictable based on a sleepiness scale score, BMI(Z), or underlying genetic defect.

Citing Articles

Cardiovascular autonomic dysfunction and sleep abnormalities in children with Prader-Willi syndrome.

Debs R, Diene G, Cortadellas J, Molinas C, Kermorgant M, Tauber M Clin Auton Res. 2024; .

PMID: 39633031 DOI: 10.1007/s10286-024-01083-8.


Complex relationship between growth hormone and sleep in children: insights, discrepancies, and implications.

Zaffanello M, Pietrobelli A, Cavarzere P, Guzzo A, Antoniazzi F Front Endocrinol (Lausanne). 2024; 14:1332114.

PMID: 38327902 PMC: 10847528. DOI: 10.3389/fendo.2023.1332114.


The Impact of Growth Hormone Therapy on Sleep-Related Health Outcomes in Children with Prader-Willi Syndrome: A Review and Clinical Analysis.

Zaffanello M, Pietrobelli A, Piacentini G, Guzzo A, Antoniazzi F J Clin Med. 2023; 12(17).

PMID: 37685570 PMC: 10488332. DOI: 10.3390/jcm12175504.


The relationship between endogenous oxytocin and vasopressin levels and the Prader-Willi syndrome behaviour phenotype.

Rice L, Agu J, Carter C, Harris J, Nazarloo H, Naanai H Front Endocrinol (Lausanne). 2023; 14:1183525.

PMID: 37313445 PMC: 10259653. DOI: 10.3389/fendo.2023.1183525.


Sleep Disorders in Children with Prader Willi Syndrome: Current Perspectives.

Ingram D, Arganbright J, Paprocki E, Halpin K Nat Sci Sleep. 2022; 14:2065-2074.

PMID: 36394064 PMC: 9662031. DOI: 10.2147/NSS.S361518.


References
1.
Nevsimalova S, Vankova J, Stepanova I, Seemanova E, Mignot E, Nishino S . Hypocretin deficiency in Prader-Willi syndrome. Eur J Neurol. 2004; 12(1):70-2. DOI: 10.1111/j.1468-1331.2004.00969.x. View

2.
Riedl S, Blumel P, Zwiauer K, Frisch H . Death in two female Prader-Willi syndrome patients during the early phase of growth hormone treatment. Acta Paediatr. 2005; 94(7):974-7. DOI: 10.1111/j.1651-2227.2005.tb02022.x. View

3.
Vgontzas A, Kales A, Seip J, Mascari M, Bixler E, Myers D . Relationship of sleep abnormalities to patient genotypes in Prader-Willi syndrome. Am J Med Genet. 1996; 67(5):478-82. DOI: 10.1002/(SICI)1096-8628(19960920)67:5<478::AID-AJMG7>3.0.CO;2-G. View

4.
Haqq A, Stadler D, Jackson R, Rosenfeld R, Purnell J, LaFranchi S . Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab. 2003; 88(5):2206-12. DOI: 10.1210/jc.2002-021536. View

5.
Carrel A, Myers S, Whitman B, Allen D . Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study. J Pediatr. 1999; 134(2):215-21. DOI: 10.1016/s0022-3476(99)70418-x. View